NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023

Rhea-AI Summary

NeuroPace, a medical device company based in Mountain View, California, is set to announce its financial results for the first quarter of 2023 on May 4, 2023. The report will be released after market close, followed by a conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). The call will be accessible through a live and archived webcast on the company's website, ensuring replay availability for at least 90 days. NeuroPace specializes in innovative treatments for epilepsy, particularly with its RNS System, aimed at offering personalized, real-time solutions to patients suffering from drug-resistant epilepsy. This advanced platform represents a significant step forward in the care of patients with seizure disorders, promoting improved outcomes.

Positive

• Anticipation of Q1 2023 financial results could indicate potential revenue growth.
• Company focuses on innovative treatments for drug-resistant epilepsy, suggesting a strong market position.

Negative

• None.

MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2023 after market close on Thursday, May 4, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.neuropace.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Gilmartin Group
Philip Trip Taylor
investors@neuropace.com   

FAQ

When will NeuroPace release its Q1 2023 financial results?

NeuroPace will report its Q1 2023 financial results on May 4, 2023, after market close.

What time is the NeuroPace conference call for the financial results?

The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 4, 2023.

How can I listen to the NeuroPace financial results webcast?

Investors can access the live and archived webcast on the NeuroPace website under the Investors section.

What is the focus of NeuroPace's medical technology?

NeuroPace focuses on transforming epilepsy treatment through its brain-responsive RNS System, which delivers personalized therapy.